Edward Ross
Analyst · Raymond James. You may proceed with your question
Good morning, Jody and good morning, everyone. Welcome to our third quarter 2019 earnings conference call. I'll open today's call with a high level commentary on our quarterly results, and then I'll cover our investment portfolio performance and conclude with comments regarding our view of the market and activity levels, as we move into the final quarter of 2019. Shelby will go into more detail about the third quarter financial results and our liquidity position. Once we have completed our prepared remarks, we'd be happy to take your questions. From my perspective during the third quarter we executed well on our strategy of building a well-diversified portfolio debt and equity investments in lower middle market businesses that we believe will perform well over the long-term, generate high levels of current and recurring investment income and offer us the opportunity to boost returns through the monetization of equity investment. In addition, we continue to execute well against our primary goals of delivering stable dividends and growing net asset value per share. Adjusted net investment income, which we define as net investment income excluding any capital gains, incentive fee attributable to realized and unrealized gains and losses was $8.7 million or $0.35 per share for the quarter compared to $8.9 million or $0.37 per share for the same period last year. As of September 30, 2019, our net asset value or NAV was $402.8 million or $16.47 per share. On September 20, 2019 Fidus paid a regular quarterly dividend of $0.39 per share, estimated spillover income for taxable income in excess of distributions was $16.9 million or $0.69 per share. Earlier this week, the Board of Directors declared a regular quarterly dividend of $0.39 per share and also declared a special dividend of $0.04 per share, both of which will be payable on December 20, 2019 to stockholders of record as of December 6, 2019. Q4 dividends bring total distributions this year to $1.60 per share, and represent the seventh consecutive year paying the special dividend. Terms of originations, we invested a total of $47 million in debt and equity securities during the quarter. In contrast to the second quarter, third quarter originations were weighted toward add on investments to eight existing portfolio companies, which amounted to roughly $36.3 million of the $47 million. Substantially all these add on investments supported M&A activity by our portfolio companies. Largest of these was a $21.5 million subordinated debt investment in allied 100. The remaining amount was invested in a new portfolio company Bandon fitness, Inc. largest franchisee of anytime fitness gyms in the United States, with 12 locations across 11 states. We invested $10.8 million in the first lien debt and common equity. Subsequent to quarter end we invested in another new portfolio company hematologic technologies, Inc., a leading provider of biologic products and GMP compliant that say element and testing services to the biopharmaceutical industry. We invested $6 million in the first lien that in common equity. As expected, we generated some capital gains during the quarter in terms of repayments and realizations we received proceeds totaling $23.5 million of which $12.7 million came from the monetization of equity positions and three portfolio companies that were sold the new private equity owners. In connection with these exit we recorded gains totaling $10.7 million in each case, we generated over three times our initial investment demonstrating the strength of our investment strategy. Just after the quarter on October 1. We exited our debt and equity investments and system plaques manufacturing company. We received payment in full of our $4.1 million on our subordinated debt investment and sold our won investments of $4.1 million, realizing a gain of approximately $2.9 million. Including our exit in simplex manufacturing we received the proceeds from the sale of equity positions totaling $16.8 million and realized gains totaling $13.6 million since the end of the second quarter. Turning to our portfolio construction and metrics, the fair value of our investment portfolio as of September 30, 2019 read $729.4 million equal 10.5% [ph] of cost. On a FairValue basis, the breakdown of the portfolio by investment type as of September 30 was as follows. First lien debt 11%, second lien debt 52%, subordinated debt 20% and equity 17%. We ended the quarter with 62 active portfolio companies, and four companies that have sold their underlying operations. This mix of investment types reflect the positioning of our portfolio to provide us with a high level of current recurring income from that investments along with the opportunity for incremental returns from our equity investments. As of September 30, 2019, we had debt investments on two portfolio companies on nonaccrual status, US Green fiber and Oaktree Medical Center equal to 1.2% of our portfolio on a fair value basis. With respect to US Green fiber in early September, we took control of the company via a recapitalization transaction investing $2.8 million, primarily in the second lien debt, alongside the previous control investor in a new investor. This recapitalization is intended to provide the company with sufficient liquidity to execute its strategic plan. Moving to our portfolio performance and track several quality measures on a quarterly basis they help us monitor the overall quality and stability and performance of our investment portfolio. First, we track the portfolios weighted average investment rating based on our internal system, under our methodology a rating of one is outperform and a rating of five is an expected loss at September 30, the weighted average investment ratio for the portfolio is 1.9 on the fair value basis in line with prior periods. Another metric, we track it to credit performance of the portfolio, which is measured by our portfolio companies combined ratio, total net debt, debt investment to total EBITDA. With the third quarter this ratio is 4.7 times compared to 4.6 times for the second quarter. The third measure, we track is the combined ratio of our portfolio companies, total EBITDA to total cash interest expense, which is indicative of the portion of our portfolio companies have an aggregate to meet their debt service obligations to us. For the third quarter this metric was 3.3 times compared to 3.8 for the second quarter, we believe the soundness of these metrics reflect our debt structuring philosophy of maintaining significant cushions to our borrower’s enterprise value in support of our capital preservation and income goals. In closing, as we look toward the end of 2019, we believe business conditions in our targeted lower middle market remained solid, providing us with opportunities to selectively grow our portfolio in a cautious and delivered manner while leveraging our experience in relationships. Our investment strategy and underwriting principles ensure that we remain focused on investing in high-quality companies that possess defensible market positions and less cyclical business models that generate excess cash flow for debt service and growth and they have positive long-term outlooks. At the same time remain focused on rotating mature equity investments into income producing assets. Overall portfolio is in good shape and well-positioned to provide us with current and recurring investment income even with the potential for softening economic conditions on the horizon. In addition, our equity portfolio continues to show promise through solid execution we intend to continue to manage the business with a long-term, with an emphasis on capital preservation in generating attractive risk-adjusted returns. Now, I turn the call over to Shelby to provide some details on our financial and operating results. Shelby?